| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Ornidazole Levo- targets anaerobic bacteria and protozoa through a mechanism involving DNA damage. The nitro group of the compound is reduced by microbial enzymes to reactive intermediates that bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis. This leads to cell death of susceptible microorganisms. The levo-isomer is the pharmacologically active enantiomer with higher potency compared to the racemic mixture.
|
|---|---|
| ln Vitro |
In vitro, Ornidazole Levo- demonstrates potent activity against a range of anaerobic bacteria and protozoa. It shows activity against Bacteroides species, Clostridium species, and other anaerobic pathogens. The compound is also active against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia. Specific MIC values for various microorganisms are not detailed in the available sources. The levo-isomer has enhanced activity compared to the dextro-isomer and the racemic mixture.
|
| ln Vivo |
In vivo, Ornidazole Levo- is used for the treatment of infections caused by anaerobic bacteria and protozoa. It is effective against trichomoniasis, amebiasis, giardiasis, and anaerobic bacterial infections. The compound is well absorbed after oral administration and achieves therapeutic concentrations in various tissues and body fluids. The levo-isomer provides improved therapeutic efficacy and tolerability compared to the racemic mixture.
|
| Enzyme Assay |
The antimicrobial susceptibility testing for Ornidazole Levo- is performed using standard broth microdilution or agar dilution methods. Anaerobic bacteria are cultured in appropriate medium under anaerobic conditions. Two-fold serial dilutions of Ornidazole Levo- are prepared in 96-well plates, and bacterial suspensions are added. Plates are incubated at 35-37°C for 48 hours under anaerobic conditions. The MIC is determined as the lowest concentration that inhibits visible growth.
|
| Cell Assay |
To evaluate the cellular activity of Ornidazole Levo-, susceptible microorganisms (such as Trichomonas vaginalis or Entamoeba histolytica) are cultured in appropriate medium. The organisms are treated with varying concentrations of Ornidazole Levo-, and cell viability is assessed by counting motile organisms or using metabolic assays. The IC50 for inhibition of growth or viability is calculated.
|
| Animal Protocol |
The in vivo efficacy of Ornidazole Levo- is evaluated in animal models of protozoal or anaerobic bacterial infections. For trichomoniasis, mice or rats are infected intravaginally with Trichomonas vaginalis and treated orally with Ornidazole Levo-. The reduction in parasite load is assessed by microscopic examination of vaginal smears. For anaerobic infections, animal models of intra-abdominal or soft tissue infections are used.
|
| ADME/Pharmacokinetics |
Ornidazole Levo- is well absorbed after oral administration and has a pharmacokinetic profile characterized by high bioavailability and long half-life. Specific pharmacokinetic parameters (e.g., Cmax, Tmax, half-life, AUC) are not detailed in the available sources. The compound has a molecular weight of 219.62 and a molecular formula of C7H10ClN3O3. It is typically stored as a powder at room temperature.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of use during lactation Ornidazole has not been approved for marketing by the U.S. Food and Drug Administration (FDA), but it is available in other countries. After intravenous administration of three doses totaling 2 grams of ornidazole during the perinatal period, the concentration of ornidazole in breast milk is low. There are currently no reports on plasma drug concentrations in lactating infants. No studies have evaluated adverse reactions of ornidazole to lactating infants, but it is speculated that they are similar to those of the closely related drug metronidazole, such as an increased risk of oral and rectal candidiasis. As with metronidazole, there are concerns about the potential mutagenicity and carcinogenicity of ornidazole in healthy infants through breast milk [1]. Experts disagree on the suitability of long-term use of ornidazole in lactating women, but avoiding breastfeeding for three days after a single dose should reduce the drug concentration in breast milk to a negligible level, as its half-life is similar to that of tinidazole. [2] Other medications are available for treating bacterial vaginosis and can be administered vaginally, thereby reducing the concentration of the drug in breast milk. ◉ Effects on breastfed infants No published information found as of the revision date. ◉ Effects on lactation and breast milk No published information found as of the revision date. Ornidazole is generally well-tolerated, with common adverse effects including nausea, headache, and metallic taste. The levo-isomer has improved tolerability compared to the racemic mixture. As a 5-nitroimidazole, it carries a risk of neurotoxicity with prolonged use. The compound is approved for clinical use in many countries for the treatment of protozoal and anaerobic bacterial infections. Standard safety precautions should be followed when handling this compound. |
| References | |
| Additional Infomation |
Reports indicate that (2S)-1-chloro-3-(2-methyl-5-nitroimidazole-1-yl)prop-2-ol exists in Streptomyces, and relevant data are available for reference.
Ornidazole Levo- is the levorotatory enantiomer of Ornidazole, a 5-nitroimidazole antibiotic with antiprotozoal and antibacterial activity. It is used in the treatment of infections caused by anaerobic bacteria and protozoa such as Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia. The levo-isomer is the active enantiomer with enhanced activity and improved tolerability compared to the racemic mixture. |
| Molecular Formula |
C7H10CLN3O3
|
|---|---|
| Molecular Weight |
219.6256
|
| Exact Mass |
219.041
|
| CAS # |
166734-83-4
|
| Related CAS # |
Ornidazole;16773-42-5
|
| PubChem CID |
6541429
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
443.2±40.0 °C at 760 mmHg
|
| Flash Point |
221.9±27.3 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
0.69
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
211
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1=NC=C([N+]([O-])=O)N1C[C@H](O)CCl
|
| InChi Key |
IPWKIXLWTCNBKN-ZCFIWIBFSA-N
|
| InChi Code |
InChI=1S/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3/t6-/m1/s1
|
| Chemical Name |
(2S)-1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-ol
|
| Synonyms |
levornidazole; Ornidazole (Levo-); Ornidazole Levo-; (S)-Ornidazole; Levo-ornidazole; (-)-Tiberal;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (455.31 mM)
H2O : 6.67 mg/mL (30.37 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 3: 10% DMSO+90% (20% SBE-β-CD in Saline): ≥ 2.5 mg/mL (11.38 mM) View More
Solubility in Formulation 4: 25 mg/mL (113.83 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5531 mL | 22.7656 mL | 45.5311 mL | |
| 5 mM | 0.9106 mL | 4.5531 mL | 9.1062 mL | |
| 10 mM | 0.4553 mL | 2.2766 mL | 4.5531 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA